prothymosin alpha comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
On 15 March 2024 cyclist Christos Volikakis was informed of an Adverse Analytical Finding on a re-analysis of a sample from the 2016 Rio Olympics. The athlete has since requested an analysis of the B sample. In 2015, the quarterback of the Florida Gators, Will Grier, was suspended for testing positive for LGD-4033, a claim that the University of Florida denies. In 2017, Joakim Noah was banned for twenty games by the NBA for testing positive for LGD-4033. In 2019, Australian swimmer Shayna Jack tested positive for LGD-4033. She denies knowingly taking the substance. In August 2019, it came to light that Canadian sprint canoeist Laurence Vincent Lapointe tested positive for LGD-4033; the athlete denies knowingly taking a forbidden substance that resulted in her suspension from competition. The athlete remarked that the National Team Training Centre purchased nutritional supplements for its athletes and denied buying or taking nutritional supplements on her own. On 27 January 2020 she was cleared of all charges. The substance was found in her results because of an exchange of bodily fluids with her boyfriend, who took LGD-4033. In January 2020, Chilean ATP tennis singles competitor Nicolás Jarry tested positive for both LGD-4033 and stanozolol. He protested at the time that the multi-vitamins from Brazil that he took on the advice of an unnamed doctor were contaminated. On 3 September 2022, sprinter Nzubechi Grace Nwokocha was provisionally suspended for the use of banned substances enobosarm and LGD-4033 by the Athletics Integrity Unit (AIU).
She is also a member and elected Trustee for the British Society for Immunology where she chairs their Immunology Taskforce. She also serves as Chair Trustee for the Vivensa Foundation. Dunn-Walters is currently the Associate Dean for Research and Innovation, Faculty of Health and Medical Sciences at the University of Surrey. During the COVID-19 pandemic, Dunn-Walters served as a scientific advisor to the Government of the United Kingdom. She was a member of the Scientific Advisory Group for Emergencies (SAGE), and Chair of the British Society for Immunology COVID-19 Taskforce. Dunn-Walters recommended all who were able to have the COVID-19 vaccine. She was elected a Fellow of the Academy of Medical Sciences in 2025.
GeV, predicting a longer proton lifetime. However, SUSY also introduces dimension 5 operators that can contribute to proton decay with much shorter decay times. To suppress these contributions extra symmetries are invoked, with the result that decays to quarks and leptons in other generation than (u, d, e,
Sources: en.wikipedia.org
=== Soil === Isolates from coal power plant soil are being recognized as pseudomonas and show that they are able to “grow on both the aliphatic and aromatic fractions of petroleum". The aliphatic fraction accounts for the most of crude oil and it is easily broken down by species of pseudomonas. Concentration of naphthene and aromatics components of crude oil noticeably decreased, implying the catabolic flexibleness of pseudomonas isolates. Salam, Obayori, Akashoro, and Okogie say that with incubation of pseudomonas isolates at 1g/L concentration for 21days, 90% of BLCO was broken down which means almost all of aliphatic fragments were vanished and aromatic fragments remarkably decreased. Although there are some microorganisms which are able to degrade crude oil, pseudomonas group shows up as it is the most adaptable. There are two main seasons which are dry and rainy in Nigeria. In the dry season, the temperature of soil varies between 30 and 45 °C, while it changes from 20 to 30 °C during the dry season. The ability of bacteria in soil to break down crude oil is remarkably affected by the average temperatures, pH, and nutrients in the soil that are quite different by seasons. For the experiment that is conducted incubation of Pseudomonas sp and Bacillus sp at the different temperature from 20 to 44 °C and for different time from 6 to 24days, both of bacteria showed the highest amount of degradation of bonny light oil at 36 °C. The amount of degradation of crude oil diversified according to the temperature.
== Polymer chemistry == In the context of polymers, "dimer" also refers to the degree of polymerization 2, regardless of the stoichiometry or condensation reactions. One case where this is applicable is with disaccharides. For example, cellobiose is a dimer of glucose, even though the formation reaction produces water:
In March 2009, the company unveiled the alternate slogan "You 'Kin Do It!" and launched a $100 million ad campaign promotion. In 2017, the company announced that it would begin testing the name of simply "Dunkin'" at some retail locations, as they would like to be thought of as a destination for coffee, its most profitable product. The branding would be implemented in other locations in the latter half of 2018 if it was successful. The brand announced that it would be known simply as Dunkin' in September 2018. In April 2018, Dunkin' Donuts teamed up with the Massachusetts shoe manufacturer, Saucony, to produce a strawberry-frosted doughnut themed running shoe to commemorate the 122nd running of the Boston Marathon. The Saucony X Dunkin' Kinvara 9 came in a doughnut box and the heel of the shoe was covered in rainbow sprinkles. The chain is a favorite among celebrities. Ben Affleck began starring in commercials for the company along with his then-wife Jennifer Lopez in February 2023. The first aired during Super Bowl LVII. They starred in a follow up that first aired during Super Bowl LVIII, along with Affleck's long-time friend, Matt Damon, and former NFL star Tom Brady. The chain then announced it would add Affleck's specific order, an iced coffee with cream, sweet cold foam, and cinnamon sugar, via its limited-time DunKings Menu. On July 29, 2025, Dunkin' launched a campaign dubbed the "King of Summer", featuring actor Gavin Casalegno advertising its fruit-flavored Summer Refreshers.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.